Does the media prefer SGMT or PHAR?

In the previous week, Sagimet Biosciences had 2 more articles in the media than Pharming Group. MarketBeat recorded 4 mentions for Sagimet Biosciences and 2 mentions for Pharming Group. Pharming Group's average media sentiment score of 1.77 beat Sagimet Biosciences' score of 0.87 indicating that Pharming Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sagimet Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pharming Group 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has better earnings & valuation, SGMT or EVO?

Sagimet Biosciences has higher earnings, but lower revenue than Evotec. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sagimet Biosciences $2M 126.41 -$51.04M -$1.34 N/A Evotec $891.97M 0.85 -$117.12M N/A N/A

Does the media prefer SGMT or EVO?

In the previous week, Evotec had 4 more articles in the media than Sagimet Biosciences. MarketBeat recorded 8 mentions for Evotec and 4 mentions for Sagimet Biosciences. Sagimet Biosciences' average media sentiment score of 0.87 beat Evotec's score of 0.20 indicating that Sagimet Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sagimet Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Evotec 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Is LBRX or SGMT more profitable?

LB Pharmaceuticals' return on equity of 0.00% beat Sagimet Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets LB Pharmaceuticals N/A N/A N/A Sagimet Biosciences N/A -37.57% -35.52%

Does the media favor LBRX or SGMT?

In the previous week, LB Pharmaceuticals had 2 more articles in the media than Sagimet Biosciences. MarketBeat recorded 6 mentions for LB Pharmaceuticals and 4 mentions for Sagimet Biosciences. Sagimet Biosciences' average media sentiment score of 0.87 beat LB Pharmaceuticals' score of 0.84 indicating that Sagimet Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LB Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sagimet Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to SGMT or DBVT?

In the previous week, Sagimet Biosciences and Sagimet Biosciences both had 4 articles in the media. Sagimet Biosciences' average media sentiment score of 0.87 beat DBV Technologies' score of 0.63 indicating that Sagimet Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sagimet Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive DBV Technologies 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is REPL or SGMT more profitable?

Sagimet Biosciences' return on equity of -37.57% beat Replimune Group's return on equity. Company Net Margins Return on Equity Return on Assets Replimune Group N/A -128.57% -82.35% Sagimet Biosciences N/A -37.57% -35.52%

Does the media refer more to REPL or SGMT?

In the previous week, Replimune Group had 2 more articles in the media than Sagimet Biosciences. MarketBeat recorded 6 mentions for Replimune Group and 4 mentions for Sagimet Biosciences. Replimune Group's average media sentiment score of 0.93 beat Sagimet Biosciences' score of 0.87 indicating that Replimune Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Replimune Group 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sagimet Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Sagimet Biosciences (SGMT) Competitors

$7.76 +0.61 (+8.53%)

Closing price 07/14/2026 04:00 PM Eastern

Extended Trading

$7.83 +0.07 (+0.91%)

As of 07/14/2026 07:56 PM Eastern

Compare

SGMT vs. PHAR, EVO, LBRX, DBVT, and REPL

Should you buy Sagimet Biosciences stock or one of its competitors? MarketBeat compares Sagimet Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sagimet Biosciences include Pharming Group (PHAR), Evotec (EVO), LB Pharmaceuticals (LBRX), DBV Technologies (DBVT), and Replimune Group (REPL). These companies are all part of the "pharmaceutical products" industry.

How does Sagimet Biosciences compare to Pharming Group?

Sagimet Biosciences (NASDAQ:SGMT) and Pharming Group (NASDAQ:PHAR) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, media sentiment, dividends, institutional ownership and earnings.

87.9% of Sagimet Biosciences shares are owned by institutional investors. Comparatively, 0.0% of Pharming Group shares are owned by institutional investors. 14.7% of Sagimet Biosciences shares are owned by company insiders. Comparatively, 2.1% of Pharming Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Pharming Group has higher revenue and earnings than Sagimet Biosciences. Sagimet Biosciences is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sagimet Biosciences	$2M	126.41	-$51.04M	-$1.34	N/A
Pharming Group	$376.13M	2.52	$2.85M	$0.16	83.81

Sagimet Biosciences currently has a consensus price target of $25.57, suggesting a potential upside of 229.53%. Pharming Group has a consensus price target of $38.33, suggesting a potential upside of 185.86%. Given Sagimet Biosciences' stronger consensus rating and higher probable upside, equities research analysts clearly believe Sagimet Biosciences is more favorable than Pharming Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sagimet Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Pharming Group	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Sagimet Biosciences had 2 more articles in the media than Pharming Group. MarketBeat recorded 4 mentions for Sagimet Biosciences and 2 mentions for Pharming Group. Pharming Group's average media sentiment score of 1.77 beat Sagimet Biosciences' score of 0.87 indicating that Pharming Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sagimet Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pharming Group	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Sagimet Biosciences has a beta of 3.35, indicating that its stock price is 235% more volatile than the broader market. Comparatively, Pharming Group has a beta of -0.04, indicating that its stock price is 104% less volatile than the broader market.

Pharming Group has a net margin of 3.30% compared to Sagimet Biosciences' net margin of 0.00%. Pharming Group's return on equity of 4.64% beat Sagimet Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sagimet Biosciences	N/A	-37.57%	-35.52%
Pharming Group	3.30%	4.64%	2.55%

Summary

Sagimet Biosciences and Pharming Group tied by winning 8 of the 16 factors compared between the two stocks.

How does Sagimet Biosciences compare to Evotec?

Sagimet Biosciences (NASDAQ:SGMT) and Evotec (NASDAQ:EVO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, valuation, analyst recommendations, media sentiment, profitability and earnings.

Sagimet Biosciences presently has a consensus target price of $25.57, indicating a potential upside of 229.53%. Evotec has a consensus target price of $7.00, indicating a potential upside of 227.10%. Given Sagimet Biosciences' stronger consensus rating and higher probable upside, research analysts clearly believe Sagimet Biosciences is more favorable than Evotec.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sagimet Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Evotec	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Sagimet Biosciences has a beta of 3.35, indicating that its share price is 235% more volatile than the broader market. Comparatively, Evotec has a beta of 1.92, indicating that its share price is 92% more volatile than the broader market.

87.9% of Sagimet Biosciences shares are held by institutional investors. Comparatively, 5.8% of Evotec shares are held by institutional investors. 14.7% of Sagimet Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Evotec had 4 more articles in the media than Sagimet Biosciences. MarketBeat recorded 8 mentions for Evotec and 4 mentions for Sagimet Biosciences. Sagimet Biosciences' average media sentiment score of 0.87 beat Evotec's score of 0.20 indicating that Sagimet Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sagimet Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Evotec	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Sagimet Biosciences has a net margin of 0.00% compared to Evotec's net margin of -26.20%. Evotec's return on equity of -24.93% beat Sagimet Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sagimet Biosciences	N/A	-37.57%	-35.52%
Evotec	-26.20%	-24.93%	-11.35%

Sagimet Biosciences has higher earnings, but lower revenue than Evotec.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sagimet Biosciences	$2M	126.41	-$51.04M	-$1.34	N/A
Evotec	$891.97M	0.85	-$117.12M	N/A	N/A

Summary

Sagimet Biosciences beats Evotec on 10 of the 14 factors compared between the two stocks.

How does Sagimet Biosciences compare to LB Pharmaceuticals?

LB Pharmaceuticals (NASDAQ:LBRX) and Sagimet Biosciences (NASDAQ:SGMT) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, institutional ownership, profitability, media sentiment, dividends and earnings.

In the previous week, LB Pharmaceuticals had 2 more articles in the media than Sagimet Biosciences. MarketBeat recorded 6 mentions for LB Pharmaceuticals and 4 mentions for Sagimet Biosciences. Sagimet Biosciences' average media sentiment score of 0.87 beat LB Pharmaceuticals' score of 0.84 indicating that Sagimet Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LB Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sagimet Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

LB Pharmaceuticals' return on equity of 0.00% beat Sagimet Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LB Pharmaceuticals	N/A	N/A	N/A
Sagimet Biosciences	N/A	-37.57%	-35.52%

LB Pharmaceuticals currently has a consensus target price of $39.50, indicating a potential upside of 23.36%. Sagimet Biosciences has a consensus target price of $25.57, indicating a potential upside of 229.53%. Given Sagimet Biosciences' higher probable upside, analysts clearly believe Sagimet Biosciences is more favorable than LB Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LB Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Sagimet Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

87.9% of Sagimet Biosciences shares are owned by institutional investors. 5.8% of LB Pharmaceuticals shares are owned by insiders. Comparatively, 14.7% of Sagimet Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

LB Pharmaceuticals has higher earnings, but lower revenue than Sagimet Biosciences. LB Pharmaceuticals is trading at a lower price-to-earnings ratio than Sagimet Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LB Pharmaceuticals	N/A	N/A	-$25.20M	-$1.73	N/A
Sagimet Biosciences	$2M	126.41	-$51.04M	-$1.34	N/A

Summary

Sagimet Biosciences beats LB Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Sagimet Biosciences compare to DBV Technologies?

Sagimet Biosciences (NASDAQ:SGMT) and DBV Technologies (NASDAQ:DBVT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings.

In the previous week, Sagimet Biosciences and Sagimet Biosciences both had 4 articles in the media. Sagimet Biosciences' average media sentiment score of 0.87 beat DBV Technologies' score of 0.63 indicating that Sagimet Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sagimet Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
DBV Technologies	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sagimet Biosciences presently has a consensus price target of $25.57, indicating a potential upside of 229.53%. DBV Technologies has a consensus price target of $48.50, indicating a potential upside of 204.65%. Given Sagimet Biosciences' higher possible upside, research analysts plainly believe Sagimet Biosciences is more favorable than DBV Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sagimet Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
DBV Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Sagimet Biosciences has higher earnings, but lower revenue than DBV Technologies. Sagimet Biosciences is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sagimet Biosciences	$2M	126.41	-$51.04M	-$1.34	N/A
DBV Technologies	$5.64M	167.13	-$146.95M	-$4.46	N/A

Sagimet Biosciences has a net margin of 0.00% compared to DBV Technologies' net margin of -2,895.37%. Sagimet Biosciences' return on equity of -37.57% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sagimet Biosciences	N/A	-37.57%	-35.52%
DBV Technologies	-2,895.37%	-129.88%	-88.84%

87.9% of Sagimet Biosciences shares are owned by institutional investors. Comparatively, 71.7% of DBV Technologies shares are owned by institutional investors. 14.7% of Sagimet Biosciences shares are owned by company insiders. Comparatively, 1.1% of DBV Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Sagimet Biosciences has a beta of 3.35, meaning that its share price is 235% more volatile than the broader market. Comparatively, DBV Technologies has a beta of -0.95, meaning that its share price is 195% less volatile than the broader market.

Summary

Sagimet Biosciences beats DBV Technologies on 11 of the 16 factors compared between the two stocks.

How does Sagimet Biosciences compare to Replimune Group?

Replimune Group (NASDAQ:REPL) and Sagimet Biosciences (NASDAQ:SGMT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.

In the previous week, Replimune Group had 2 more articles in the media than Sagimet Biosciences. MarketBeat recorded 6 mentions for Replimune Group and 4 mentions for Sagimet Biosciences. Replimune Group's average media sentiment score of 0.93 beat Sagimet Biosciences' score of 0.87 indicating that Replimune Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Replimune Group	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sagimet Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

92.5% of Replimune Group shares are held by institutional investors. Comparatively, 87.9% of Sagimet Biosciences shares are held by institutional investors. 5.2% of Replimune Group shares are held by insiders. Comparatively, 14.7% of Sagimet Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Sagimet Biosciences has higher revenue and earnings than Replimune Group. Sagimet Biosciences is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Replimune Group	N/A	N/A	-$313.94M	-$3.38	N/A
Sagimet Biosciences	$2M	126.41	-$51.04M	-$1.34	N/A

Sagimet Biosciences' return on equity of -37.57% beat Replimune Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Replimune Group	N/A	-128.57%	-82.35%
Sagimet Biosciences	N/A	-37.57%	-35.52%

Replimune Group has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market. Comparatively, Sagimet Biosciences has a beta of 3.35, indicating that its stock price is 235% more volatile than the broader market.

Replimune Group currently has a consensus target price of $8.13, indicating a potential downside of 17.68%. Sagimet Biosciences has a consensus target price of $25.57, indicating a potential upside of 229.53%. Given Sagimet Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Sagimet Biosciences is more favorable than Replimune Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Replimune Group	2 Sell rating(s)	6 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Sagimet Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Summary

Sagimet Biosciences beats Replimune Group on 10 of the 14 factors compared between the two stocks.

Get Sagimet Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SGMT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SGMT vs. The Competition

Export

Metric	Sagimet Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$232.98M	$3.68B	$6.86B	$12.44B
Dividend Yield	N/A	2.19%	2.68%	8.42%
P/E Ratio	-5.79	20.98	27.01	24.38
Price / Sales	126.41	311.10	519.43	91.92
Price / Cash	N/A	143.66	48.59	59.36
Price / Book	2.27	8.54	10.80	6.33
Net Income	-$51.04M	$23.83M	$3.59B	$331.02M
7 Day Performance	4.30%	-2.77%	-1.47%	-0.33%
1 Month Performance	19.94%	5.85%	2.78%	-1.29%
1 Year Performance	-18.23%	52.15%	28.50%	21.30%

Sagimet Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SGMT Sagimet Biosciences	3.3588 of 5 stars	$7.76 +8.5%	$25.57 +229.5%	-18.0%	$232.98M	$2M	N/A	8
PHAR Pharming Group	3.451 of 5 stars	$14.41 +0.7%	$38.33 +166.1%	+29.6%	$1.02B	$376.13M	90.04	280
EVO Evotec	3.3698 of 5 stars	$2.84 -2.7%	$7.00 +146.5%	-48.1%	$1.01B	$891.97M	N/A	4,553	News Coverage Analyst Downgrade Gap Down
LBRX LB Pharmaceuticals	1.9219 of 5 stars	$34.30 +2.7%	$39.50 +15.2%	N/A	$984.15M	N/A	N/A	16	Gap Up
DBVT DBV Technologies	4.0244 of 5 stars	$16.56 +6.1%	$48.50 +192.9%	+50.5%	$980.52M	$5.64M	N/A	80	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SGMT) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sagimet Biosciences (SGMT) Competitors

SGMT vs. PHAR, EVO, LBRX, DBVT, and REPL

How does Sagimet Biosciences compare to Pharming Group?

Summary

How does Sagimet Biosciences compare to Evotec?

Summary

How does Sagimet Biosciences compare to LB Pharmaceuticals?

Summary

How does Sagimet Biosciences compare to DBV Technologies?

Summary

How does Sagimet Biosciences compare to Replimune Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGMT vs. The Competition

Sagimet Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sagimet Biosciences (SGMT) Competitors

SGMT vs. PHAR, EVO, LBRX, DBVT, and REPL

How does Sagimet Biosciences compare to Pharming Group?

Do insiders and institutionals hold more shares of SGMT or PHAR?

Which has preferable earnings & valuation, SGMT or PHAR?

Do analysts recommend SGMT or PHAR?

Does the media prefer SGMT or PHAR?

Which has more volatility & risk, SGMT or PHAR?

Is SGMT or PHAR more profitable?

Summary

How does Sagimet Biosciences compare to Evotec?

Do analysts prefer SGMT or EVO?

Which has more volatility and risk, SGMT or EVO?

Do insiders & institutionals believe in SGMT or EVO?

Does the media prefer SGMT or EVO?

Is SGMT or EVO more profitable?

Which has better earnings & valuation, SGMT or EVO?

Summary

How does Sagimet Biosciences compare to LB Pharmaceuticals?

Does the media favor LBRX or SGMT?

Is LBRX or SGMT more profitable?

Do analysts prefer LBRX or SGMT?

Do insiders and institutionals believe in LBRX or SGMT?

Which has stronger earnings & valuation, LBRX or SGMT?

Summary

How does Sagimet Biosciences compare to DBV Technologies?

Does the media refer more to SGMT or DBVT?

Do analysts prefer SGMT or DBVT?

Which has better valuation & earnings, SGMT or DBVT?

Is SGMT or DBVT more profitable?

Do insiders & institutionals believe in SGMT or DBVT?

Which has more risk and volatility, SGMT or DBVT?

Summary

How does Sagimet Biosciences compare to Replimune Group?

Does the media refer more to REPL or SGMT?

Do insiders and institutionals hold more shares of REPL or SGMT?

Which has higher earnings & valuation, REPL or SGMT?

Is REPL or SGMT more profitable?

Which has more volatility & risk, REPL or SGMT?

Do analysts recommend REPL or SGMT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGMT vs. The Competition

Sagimet Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools